Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2025PharmaceuticalsOpen Access

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAmira B. KassemDamanhour UniversityHMHebatallah Ahmed Mohamed MoustafaBadr University in CairoATAmany M TawfeikAl-Azhar University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kassem et al. (2025) studied this question.

synapsesocial.com/papers/6a828913aa66c98ddba0bd2chttps://doi.org/10.3390/ph18040539
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions2018 · 61 citations
  2. 2Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy2011 · 489 citations
  3. 3Optimizing Patient Education of Oncology Medications: A Patient Perspective2018 · 31 citations